Medpace Holdings, Inc. $MEDP Shares Bought by Smith Group Asset Management LLC

Smith Group Asset Management LLC boosted its position in shares of Medpace Holdings, Inc. (NASDAQ:MEDP) by 9.3% in the 1st quarter, Holdings Channel.com reports. The institutional investor owned 103,603 shares of the company’s stock after buying an additional 8,821 shares during the period. Medpace comprises 2.5% of Smith Group Asset Management LLC’s portfolio, making the stock its 12th biggest holding. Smith Group Asset Management LLC’s holdings in Medpace were worth $49,749,000 at the end of the most recent reporting period.

A number of other hedge funds have also made changes to their positions in MEDP. AQR Capital Management LLC lifted its position in shares of Medpace by 31.6% in the fourth quarter. AQR Capital Management LLC now owns 1,349,703 shares of the company’s stock valued at $758,061,000 after acquiring an additional 324,293 shares in the last quarter. Wasatch Advisors LP increased its position in shares of Medpace by 14.0% during the second quarter. Wasatch Advisors LP now owns 945,814 shares of the company’s stock worth $296,853,000 after purchasing an additional 116,354 shares in the last quarter. Geode Capital Management LLC raised its stake in Medpace by 3.8% in the 4th quarter. Geode Capital Management LLC now owns 667,298 shares of the company’s stock valued at $374,836,000 after purchasing an additional 24,625 shares during the last quarter. Invesco Ltd. raised its stake in Medpace by 18.9% in the 3rd quarter. Invesco Ltd. now owns 537,407 shares of the company’s stock valued at $276,313,000 after purchasing an additional 85,517 shares during the last quarter. Finally, Renaissance Technologies LLC lifted its holdings in Medpace by 8.3% in the 1st quarter. Renaissance Technologies LLC now owns 504,668 shares of the company’s stock valued at $242,337,000 after purchasing an additional 38,760 shares in the last quarter. Institutional investors and hedge funds own 77.98% of the company’s stock.

Analysts Set New Price Targets

Several equities research analysts have issued reports on the stock. BMO Capital Markets lifted their target price on shares of Medpace from $400.00 to $600.00 and gave the stock a “market perform” rating in a research note on Friday. Deutsche Bank Aktiengesellschaft reiterated a “hold” rating and issued a $535.00 target price on shares of Medpace in a research report on Thursday, July 23rd. Truist Financial boosted their price target on shares of Medpace from $462.00 to $609.00 and gave the stock a “hold” rating in a research report on Friday, July 24th. Robert W. Baird upped their price objective on shares of Medpace from $547.00 to $624.00 and gave the company a “neutral” rating in a research note on Friday, July 24th. Finally, Barclays set a $600.00 price objective on shares of Medpace in a report on Thursday, July 23rd. Two research analysts have rated the stock with a Buy rating and eleven have issued a Hold rating to the company. According to MarketBeat, Medpace has a consensus rating of “Hold” and a consensus price target of $584.18.

Medpace Stock Performance

NASDAQ MEDP opened at $570.97 on Wednesday. The stock’s fifty day moving average is $498.48 and its two-hundred day moving average is $493.41. The firm has a market capitalization of $15.94 billion, a P/E ratio of 33.47, a price-to-earnings-growth ratio of 2.63 and a beta of 1.15. Medpace Holdings, Inc. has a fifty-two week low of $373.00 and a fifty-two week high of $677.90.

Medpace (NASDAQ:MEDP) last issued its earnings results on Wednesday, July 22nd. The company reported $4.25 earnings per share (EPS) for the quarter, topping analysts’ consensus estimates of $3.98 by $0.27. Medpace had a return on equity of 110.15% and a net margin of 17.67%.The business had revenue of $707.33 million during the quarter, compared to the consensus estimate of $689.51 million. During the same period last year, the company earned $3.10 EPS. The company’s revenue for the quarter was up 17.2% on a year-over-year basis. Medpace has set its FY 2026 guidance at 17.250-17.950 EPS. As a group, sell-side analysts forecast that Medpace Holdings, Inc. will post 17.55 EPS for the current year.

Insider Activity

In related news, General Counsel Stephen P. Ewald sold 16,349 shares of the company’s stock in a transaction dated Thursday, May 28th. The shares were sold at an average price of $450.00, for a total value of $7,357,050.00. Following the completion of the sale, the general counsel owned 20,343 shares of the company’s stock, valued at approximately $9,154,350. This represents a 44.56% decrease in their ownership of the stock. The sale was disclosed in a document filed with the SEC, which can be accessed through this link. Corporate insiders own 20.50% of the company’s stock.

Medpace Company Profile

Medpace Holdings, Inc (NASDAQ: MEDP) is a global contract research organization (CRO) that provides comprehensive clinical development services to biotechnology, pharmaceutical and medical device companies. The company supports clinical trials across all phases (I–IV), offering end-to-end solutions designed to streamline the development process and accelerate the delivery of new therapies to market.

Medpace’s core service offerings include clinical pharmacology, regulatory affairs consulting, project management, central laboratory services, imaging, data management and biostatistics, pharmacovigilance and medical writing.